Tenet Healthcare (NYSE:THC) Upgraded at Zacks Research

Tenet Healthcare (NYSE:THC) was upgraded by stock analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a note issued to investors on Tuesday,Zacks.com reports.

Several other equities analysts have also issued reports on THC. Truist Financial lifted their price target on Tenet Healthcare from $270.00 to $290.00 and gave the company a “buy” rating in a research note on Tuesday, July 28th. KeyCorp decreased their price target on shares of Tenet Healthcare from $250.00 to $225.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. Wells Fargo & Company raised their price objective on Tenet Healthcare from $231.00 to $281.00 and gave the stock an “overweight” rating in a research report on Monday, August 3rd. Wall Street Zen upgraded shares of Tenet Healthcare from a “buy” rating to a “strong-buy” rating in a report on Monday, August 3rd. Finally, TD Cowen boosted their price target on Tenet Healthcare from $233.00 to $263.00 and gave the company a “buy” rating in a research note on Monday, July 27th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $272.25.

Tenet Healthcare Stock Up 2.9%

Shares of NYSE THC opened at $266.87 on Tuesday. Tenet Healthcare has a 52 week low of $157.58 and a 52 week high of $269.31. The stock’s fifty day moving average is $205.96 and its 200 day moving average is $202.93. The company has a debt-to-equity ratio of 2.00, a quick ratio of 1.35 and a current ratio of 1.41. The stock has a market capitalization of $21.49 billion, a P/E ratio of 10.29, a PEG ratio of 0.99 and a beta of 1.23.

Tenet Healthcare (NYSE:THC) last announced its quarterly earnings data on Thursday, July 23rd. The company reported $6.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.26 by $1.86. Tenet Healthcare had a net margin of 10.27% and a return on equity of 26.76%. The firm had revenue of $6.04 billion for the quarter, compared to the consensus estimate of $5.43 billion. During the same period in the prior year, the company posted $4.02 earnings per share. The business’s revenue for the quarter was up 6.8% on a year-over-year basis. Tenet Healthcare has set its FY 2026 guidance at 20.300-21.690 EPS. Sell-side analysts forecast that Tenet Healthcare will post 21.07 earnings per share for the current fiscal year.

Insider Buying and Selling at Tenet Healthcare

In other Tenet Healthcare news, EVP Lisa Y. Foo sold 10,000 shares of the business’s stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $258.03, for a total value of $2,580,300.00. Following the transaction, the executive vice president owned 32,053 shares of the company’s stock, valued at approximately $8,270,635.59. The trade was a 23.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Tammy Romo sold 2,500 shares of the firm’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $260.83, for a total value of $652,075.00. Following the sale, the director directly owned 28,284 shares of the company’s stock, valued at approximately $7,377,315.72. This represents a 8.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 41,375 shares of company stock valued at $9,793,347 in the last ninety days. 0.97% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Tenet Healthcare

Several institutional investors have recently added to or reduced their stakes in THC. Price T Rowe Associates Inc. MD boosted its holdings in Tenet Healthcare by 1.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,490,350 shares of the company’s stock worth $1,488,484,000 after buying an additional 119,809 shares during the period. Boston Partners raised its holdings in shares of Tenet Healthcare by 15.7% during the 4th quarter. Boston Partners now owns 3,642,136 shares of the company’s stock valued at $723,804,000 after buying an additional 494,581 shares in the last quarter. AQR Capital Management LLC boosted its stake in shares of Tenet Healthcare by 20.3% in the 4th quarter. AQR Capital Management LLC now owns 2,256,539 shares of the company’s stock valued at $448,419,000 after purchasing an additional 380,116 shares in the last quarter. Ameriprise Financial Inc. grew its stake in shares of Tenet Healthcare by 8.0% during the second quarter. Ameriprise Financial Inc. now owns 2,119,423 shares of the company’s stock valued at $373,020,000 after buying an additional 157,109 shares during the last quarter. Finally, Norges Bank bought a new position in Tenet Healthcare during the 4th quarter worth approximately $248,494,000. 95.44% of the stock is owned by hedge funds and other institutional investors.

About Tenet Healthcare

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.